Viking Therapeutics Inc (VKTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $28.99 (-1.26%), Market cap $3.68B, 52-week low–high $23.09 ~ $42.09.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metab
Financial statements, price targets, institutional (13F) holdings and related news for Viking Therapeutics Inc are updated in real time on BlackAll Trade.
Viking Therapeutics Inc trades at $28.99 (-1.26%). Real-time quotes and charts are available on BlackAll Trade.
Viking Therapeutics Inc has a market cap of about $3.68B.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally